Refine
Has Fulltext
- yes (12)
Is part of the Bibliography
- yes (12)
Document Type
- Journal article (12)
Keywords
- Auflösungsraten (1)
- Candida albicans (1)
- Candida auris (1)
- Cutaneous leishmaniasis (1)
- Enterobacteriaceae (1)
- Escherichia coli (1)
- Festkörper-NMR (1)
- Klebsiella pneumoniae (1)
- Mizellen (1)
- Nahordnung (1)
- Paeonia (1)
- Polymere (1)
- acids (1)
- activation (1)
- amber codon suppression (1)
- amber light (1)
- antifungal drug (1)
- antimicrobial resistance (1)
- autoinjector (1)
- azobenzenes (1)
- bile (1)
- bile salt (1)
- bio-orthogonal chemistry (1)
- biocide polyhexamethylene biguanide (1)
- colloid (1)
- decafluoroazobezene (1)
- dendritic cells (1)
- dissolution (1)
- dissolution rates (1)
- drug-delivery systems (1)
- drugs (1)
- excipient (1)
- experimental visceral leishmaniasis (1)
- flux (1)
- forms (1)
- gallotannins (1)
- high-throughput screening (1)
- in situ guided tissue regeneration (1)
- in vitro-in vivo correlation (1)
- isolation (1)
- mesenchymal tissues (1)
- micelles (1)
- nerve agent (1)
- online monitoring system (1)
- oxime (1)
- paromomycin (1)
- peptide stapling (1)
- perfluoroarylation (1)
- pharmacokinetics (1)
- photocontrol (1)
- polymer drug interaction (1)
- polymers (1)
- protein engineering (1)
- rat study (1)
- regenerative medicine (1)
- resistance (1)
- response surface (1)
- scaffolds (1)
- short-range order (1)
- simulated intestinal fluid (1)
- solid-state NMR spectroscopy (1)
- solubility (1)
- stem cells (1)
- strategy (1)
- structural elucidation (1)
- therapy (1)
- topical treatment (1)
- transport (1)
- unnatural amino acid (1)
Institute
- Institut für Pharmazie und Lebensmittelchemie (11)
- Institut für Molekulare Infektionsbiologie (3)
- Institut für Organische Chemie (3)
- Institut für Anorganische Chemie (1)
- Institut für Funktionsmaterialien und Biofabrikation (1)
- Lehrstuhl für Orthopädie (1)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (1)
Sonstige beteiligte Institutionen
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-9708 Wuerzburg, Germany (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-97080 Wuerzburg, Germany (1)
- Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, DE-37077 Goetingen, Germany (1)
- Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland (1)
Background
Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan parasites of the genus Leishmania. CL causes enormous suffering in many countries worldwide. There is no licensed vaccine against CL, and the chemotherapy options show limited efficacy and high toxicity. Localization of the parasites inside host cells is a barrier to most standard chemo- and immune-based interventions. Hence, novel drugs, which are safe, effective and readily accessible to third-world countries and/or drug delivery technologies for effective CL treatments are desperately needed.
Methodology/Principal
Findings Here we evaluated the antileishmanial properties and delivery potential of polyhexamethylene biguanide (PHMB; polyhexanide), a widely used antimicrobial and wound antiseptic, in the Leishmania model. PHMB showed an inherent antileishmanial activity at submicromolar concentrations. Our data revealed that PHMB kills Leishmania major (L. major) via a dual mechanism involving disruption of membrane integrity and selective chromosome condensation and damage. PHMB's DNA binding and host cell entry properties were further exploited to improve the delivery and immunomodulatory activities of unmethylated cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN). PHMB spontaneously bound CpG ODN, forming stable nanopolyplexes that enhanced uptake of CpG ODN, potentiated antimicrobial killing and reduced host cell toxicity of PHMB.
Conclusions
Given its low cost and long history of safe topical use, PHMB holds promise as a drug for CL therapy and delivery vehicle for nucleic acid immunomodulators.
In situ guided tissue regeneration, also addressed as in situ tissue engineering or endogenous regeneration, has a great potential for population-wide “minimal invasive” applications. During the last two decades, tissue engineering has been developed with remarkable in vitro and preclinical success but still the number of applications in clinical routine is extremely small. Moreover, the vision of population-wide applications of ex vivo tissue engineered constructs based on cells, growth and differentiation factors and scaffolds, must probably be deemed unrealistic for economic and regulation-related issues. Hence, the progress made in this respect will be mostly applicable to a fraction of post-traumatic or post-surgery situations such as big tissue defects due to tumor manifestation. Minimally invasive procedures would probably qualify for a broader application and ideally would only require off the shelf standardized products without cells. Such products should mimic the microenvironment of regenerating tissues and make use of the endogenous tissue regeneration capacities. Functionally, the chemotaxis of regenerative cells, their amplification as a transient amplifying pool and their concerted differentiation and remodeling should be addressed. This is especially important because the main target populations for such applications are the elderly and diseased. The quality of regenerative cells is impaired in such organisms and high levels of inhibitors also interfere with regeneration and healing. In metabolic bone diseases like osteoporosis, it is already known that antagonists for inhibitors such as activin and sclerostin enhance bone formation. Implementing such strategies into applications for in situ guided tissue regeneration should greatly enhance the efficacy of tailored procedures in the future.